Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Hourly Market Review - Nov 12, 2024 12 PM

Market BriefTuesday, Nov 12, 2024 12:00 pm ET

1min read

Movers of the hour:

Taysha Gene is up 31.95% at $2.15.

Altimmune is up 24.63% at $9.16.

Shopify is up 24.43% at $111.97.

Zevia is up 24.22% at $2.39.

Mercurity Fintech is up 22.67% at $2.87.

Here are the top stocks upgraded by Wall Street analyst:

Nvidia has received a rating of Buy from Morgan Stanley with target price increased to $160 from $150.

Nvidia has received a rating of Buy from Piper Sandler with target price increased to $175 from $140.

Nvidia has received a rating of Strong Buy from Melius Research with target price increased to $185 from $165.

Nvidia has received a rating of Strong Buy from UBS with target price increased to $185 from $150.

Nvidia has received a rating of Strong Buy from B of A Securities with target price increased to $190 from $165.

Nvidia has received a rating of Strong Buy from Goldman Sachs with target price increased to $150 from $135.

Apple has received a rating of Strong Buy from Needham with target price increased to $260 from $260.

Apple has received a rating of Strong Buy from Rosenblatt with target price increased to $262 from $261.

Apple has received a rating of Sell from Barclays with target price dropped to $184 from $186.

Apple has received a rating of Neutral from Maxim Group with target price increased to $215 from $203.

Comments

Add a public comment...

Post

DaddyLungLegs

11/12

Shopify股票走高，此前公司报出了第三季度销售数据，表现超出市场预期。营收为2.16亿美元，而去年同期为2.11亿美元。每股收益为0.64美元，而去年同期为0.27美元。

chrisbaseball7

UBS initiated coverage on Altimmune with a $26 price target. The company recently completed Phase 2 trials for its obesity treatment, and Phase 3 trial design has been finalized by the FDA, which will involve 5000 participants in the most innovative GLP-1 trial to date. Altimmune's drug in development, Pemvidutide, has the potential to: - Help users lose weight - Preserve muscle mass more effectively than a standard diet and exercise regimen - Allow users to discontinue statin medication - Reduce snoring and improve all serum lipids - Facilitate quality weight loss, setting it apart from the next generation of GLP-1 drugs, which have been known to cause undesirable side effects like hanging skin and muscle loss (as seen in some Ozempic users).

Anonym0us_amongus

Altimmune is on the radar for a potential squeeze, with phase 3 trials for Pemvidutide, an emerging weight loss and NASH treatment, kicking off in the next quarter. This drug holds immense promise, and FDA approval for the 5000 patient trial is expected soon. Data readouts for the MASH indication are anticipated in Q2 2025, which could make this stock a prime takeover target. The company has already rejected outright acquisition offers, indicating their intent to ride this molecule for all it's worth. In a market where obesity is a growing concern, Altimmune's potential value is massive; targeting multiple indications with one drug, their pipeline is as solid as they come. Do your due diligence, because this one has the potential to be a real game-changer.

gameon-manhattan

$SHOP has seen a 150-point movement today.

caollero

Well, it looks like Nvidia is the belle of the ball today. Can't wait to see how Apple's conflicting ratings play out. In the meantime, I'm over here watching my Nvidia stocks soar

BenGrahamButler

Taysha Gene up 31.95%... what's behind this surge? Anyone have insights on this stock? Considering buying in but want to understand the driving factors first.

TeslaCoin1000000

Shopify up over 24% today? I'm happy to see the growth, but is this sustainable? Not sure, but enjoying the ride for now!

mattko

Apple gets a Strong Buy from Needham but a Sell from Barclays... makes me question the overall sentiment. Need more time to analyze before making a move.

West-Bodybuilder-867

Interesting to see such widespread bullish sentiment on Nvidia. Will wait for a slight dip to enter, don't want to buy in at a potential peak.

Mean_Dip_7001

Nvidia is on FIRE! All these upgrades are just the beginning, $190 by year-end is conservative, IMO. Buying more today!

No More Comment